Innovation spurs novel nontraditional applications
The inherent strengths of ultrasound-low cost, wide availability,nonionizing radiation-make this modality a favorite to getthe diagnostic ball rolling.
The inherent strengths of ultrasound-low cost, wide availability, nonionizing radiation-make this modality a favorite to get the diagnostic ball rolling. Technological advances headed for the RSNA exhibit floor will give added impetus to its use, as engineers have tackled some of sonography's most vexing shortfalls: lack of reproducibility from one user to another, and distinguishing anatomical structures.
- Breast imaging tools. Algorithms and automation bring out details in dense or fatty breasts that may reduce the need to perform biopsies of suspicious lesions found on mammography.
- Streamlining procedures increases efficiency. Preprogramming and intelligent software ease the tedium of ultrasound scans, reducing key strokes and cutting exam time. A side benefit, greater reproducibility, comes from less dependence on the user's skill set.
- The power of fusion. The real-time advantages of ultrasound merge with the anatomical clarity provided by CT and MR, raising the potential of greater accuracy during interventions.
-GF
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
